CoChat
Sign Up
Cited by 134Diabetes Treatment and ManagementGallbladder and Bile Duct DisordersCholangiocarcinoma and Gallbladder Cancer Studies

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus.

Open access
Faillie, Jean-Luc, Yu, Oriana H., Yin, Hui, Hillaire-Buys, Dominique, Barkun, Alan, Azoulay, Laurent·2016·JAMA Internal Medicine
DOI 10.1001/jamainternmed.2016.1531
Open this paper in CoChat — free account

Abstract

IMPORTANCE: The use of dipeptidyl-peptidase-4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues-a group of drugs used in the management of type 2 diabetes mellitus-may be associated with an increased risk of bile duct and gallbladder disease. To date, no observational study has assessed this possible association. OBJECTIVE: To determine whether the use of DPP-4 inhibitors and GLP-1 analogues is associated with an increased risk of incident bile duct and gallbladder disease in patients with type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: A population-based cohort study linked the United Kingdom Clinical Practice Research Datalink with the Hospital Episodes Statistics database, yielding a cohort of 71 369 patients, 18 years or older, initiating an antidiabetic drug (including oral and injectable agents) between January 1, 2007, and March 31, 2014. EXPOSURES: Current use of DPP-4 inhibitors and GLP-1 analogues (alone or in combination therapy) compared with current use of at least 2 oral antidiabetic drugs. MAIN OUTCOMES AND MEASURES: Time-dependent Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% CIs of incident bile duct or gallbladder events (cholelithiasis, cholecystitis, cholangitis) causing hospitalization, comparing current use of DPP-4 inhibitors and GLP-1 analogues with current use of at least 2 oral antidiabetic drugs. RESULTS: During 227 994 person-years of follow-up, 853 of the 71 369 patients were hospitalized for bile duct and gallbladder disease (incidence rate per 1000 person-years, 3.7; 95% CI, 3.5-4.0). Current use of DPP-4 inhibitors was not associated with an increased risk of bile duct and gallbladder disease compared with current use of at least 2 oral antidiabetic drugs (3.6 vs 3.3 per 1000 person-years; adjusted HR, 0.99; 95% CI, 0.75-1.32). In contrast, the use of GLP-1 analogues was associated with an increased risk of bile duct and gallbladder disease compared with current use of at least 2 oral antidiabetic drugs (6.1 vs 3.3 per 1000 person-years; adjusted HR, 1.79; 95% CI, 1.21-2.67). In a secondary analysis, GLP-1 analogues were also associated with an increased risk of cholecystectomy (adjusted HR, 2.08; 95% CI, 1.08-4.02). CONCLUSIONS AND RELEVANCE: The use of GLP-1 analogues was associated with an increased risk of bile duct and gallbladder disease. Physicians should be aware of this potential adverse event when prescribing these drugs.

Overview

Integrity signals

Registry

Crossref · 10.1001/jamainternmed.2016.1531

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Flagged first, then by citations

Show all 26 references

Cited by

Sorted by citations

Items 101–134 of 134

Related

See all

Metadata

Authors
Faillie, J.-L., Yu, O. H., Yin, H., Hillaire-Buys, D., Barkun, A., & Azoulay, L.
Affiliations
  • Université de Montpellier (FR)
  • Jewish General Hospital (CA)
  • Department of Medical Pharmacology and Toxicology, Montpellier University Hospital, Montpellier, France5Institut National de la Santé et de la Récherche Médicale (INSERM), Unité 1058, Faculty of Medicine, University Montpellier 1, Montpellier, France
  • McGill University Health Centre (CA)
Corresponding author
Azoulay, Laurent
ORCID
Venue
JAMA Internal Medicine
Publisher
American Medical Association (AMA)
Published
2016-10-01
Volume
176
Issue
10
Pages
1474
ISSN
2168-6106 (ISSN-L)
DOI
10.1001/jamainternmed.2016.1531
OpenAlex
W2485875310
Cited by
134
References
26
Citations by year
2026: 12 · 2025: 19 · 2024: 21 · 2023: 10 · 2022: 23 · 2021: 10 · 2020: 9 · 2019: 10 · 2018: 10 · 2017: 5 · 2016: 5
FWCI
10.07
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • JAMA Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Gastroenterology › Gallbladder and Bile Duct Disorders
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Keywords
gallbladder disease, type 2 diabetes, DPP-4 inhibitors, GLP-1 receptor agonists, gallstones, cholecystitis, cholangitis, drug safety, antidiabetic drugs, hospitalization risk, oral antidiabetic drugs, drug-drug interactions, adverse drug reactions
MeSH terms
Adult, Bile Duct Diseases, Cholecystectomy, Diabetes Mellitus, Type 2, Female, Gallbladder Diseases, United Kingdom, Humans, Hypoglycemic Agents, Male, Cohort Studies, Incidence, Proportional Hazards Models, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review